Latest Trials Latest NewsFAQ

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin detemir

First Posted Date: 2010-01-06

Last Posted Date: 2017-01-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 63

Registration Number: NCT01043510

Locations: 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: anti-IL-20

First Posted Date: 2009-12-24

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 16

Registration Number: NCT01038674

Locations: 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland

A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: NN9924 (oral)
Drug: placebo
Drug: NN9924 (s.c.)
Drug: NN9924 (i.v.)

First Posted Date: 2009-12-23

Last Posted Date: 2019-01-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 155

Registration Number: NCT01037582

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

Phase 1

Completed

Conditions: Healthy
Growth Hormone Disorder

Interventions: Drug: placebo
Drug: NNC126-0083
Drug: Norditropin® SimpleXx®

First Posted Date: 2009-12-17

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT01034202

Locations: 🇩🇰
Novo Nordisk Investigational Site, Hvidovre, Denmark

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2009-12-14

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 39

Registration Number: NCT01030926

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Phase 1

Completed

Conditions: Healthy
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: NN1952
Drug: insulin aspart
Drug: placebo

First Posted Date: 2009-12-09

Last Posted Date: 2017-07-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT01028404

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle

Phase 4

Completed

Conditions: Diabetes
Delivery Systems
Healthcare Professionals

First Posted Date: 2009-12-02

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 78

Registration Number: NCT01024218

Locations: 🇩🇰
Novo Nordisk Investigational Site, København, Denmark

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: gliclazide
Drug: repaglinide

First Posted Date: 2009-12-01

Last Posted Date: 2014-07-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 440

Registration Number: NCT01022762

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 1

Withdrawn

Conditions: Inflammation
Systemic Lupus Erythematosus

Interventions: Drug: NNC 0151-0000-0000
Drug: placebo

First Posted Date: 2009-11-23

Last Posted Date: 2014-08-15

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT01018238

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Lake Success, New York, United States

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

Completed

Conditions: Growth Hormone Disorder
Pituitary Dwarfism
Hypopituitarism

Interventions: Drug: somatropin

First Posted Date: 2009-11-09

Last Posted Date: 2017-04-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22960

Registration Number: NCT01009905

Locations: 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy